We’re initially advancing our CAR-NE platform in glioblastoma – one of the most aggressive and treatment-resistant solid tumors – where the need for effective drug delivery is especially urgent.

Given the platform’s ability to penetrate dense tumor tissue, we see broad potential across multiple solid tumor types, including those traditionally excluded from immune-based therapies.